Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term effects of lidocaine infusions given during and after surgery to reduce moderate or severe chronic post-surgical pain in adult women undergoing elective breast cancer surgery. This large, international, randomized, double-blind trial aims to detect a meaningful reduction in chronic pain one year after surgery and also assesses safety, pain relief, opioid use, nerve-related pain symptoms, psychological health, and quality of life. Participants receive either a lidocaine infusion starting with an intravenous bolus after anesthesia induction, continuing with an intraoperative intravenous infusion, and followed by a post-operative subcutaneous infusion for up to 24 hours. The lidocaine dosing is adjusted by lean body weight with a cap, while the comparison group receives a saline placebo infusion following the same schedule. Day-case surgeries receive only the intraoperative treatments without the post-operative infusion. During the trial, participants will be monitored for pain severity, opioid consumption, nerve-related symptoms, psychological distress, physical functioning, quality of life, safety events, and health care costs up to one year after surgery. The primary outcome is the incidence of moderate or severe chronic post-surgical pain reported at one year. Assessments include patient-reported outcomes, pain scores at 24 hours postoperatively, and opioid use at various timepoints. The total participation duration extends up to one year after surgery.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.